Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, Professor Francois Venter

Conditions

HIV-1 InfectionHIV-1-infection

Phase 2

Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)

CompletedNCT02629822

Merck Sharp & Dohme LLCHIV-1 Infection

Start: 2016-01-14End: 2020-10-28Updated: 2021-10-26

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

CompletedNCT03272347

Merck Sharp & Dohme LLCHIV-1 Infection

Start: 2017-11-27End: 2022-03-09Updated: 2023-03-29

Phase 3

DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV

CompletedNCT04433780

Professor Francois VenterHIV-1-infection

Start: 2021-01-04End: 2023-03-31Updated: 2023-08-03

Related Papers

Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine

JAIDS Journal of Acquired Immune Deficiency Syndromes2021-12-0824 citations

Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.

2021-05-1433 citations